

# CaMKK2 as a target for cancer immunotherapy

Tumor cells have the remarkable ability to block the immune system, and in such a way escape the immune response. This is a major problem that causes cancer development and metastasis. The ability of tumor cells to blunt the immune response is also a major limitation for the recent immune-therapeutic approaches, including anti-cancer vaccines and immune-check point inhibitors. This invention is aimed at preventing the detrimental effects of tumor on immune cells, and in such a way at activating the anti-tumor immune response. The invention can be used as monotherapy to promote the anti-cancer immune response, or in association with other anti-cancer therapies, including radio-chemo- and immune-therapies.

## Publications

- [U.S. Patent Application US16/323,482](#)

# Duke

## LICENSING & VENTURES

### Duke File (IDF) #

T-004928

### Inventor(s)

- Racioppi, Luigi
- Chao, Nelson
- Huang, Wei
- McDonnell, Donald
- Nelson, Erik

### College

School of Medicine (SOM)

### For more information please contact

Jung, Jee  
919-623-6275  
[jee.jung@duke.edu](mailto:jee.jung@duke.edu)